Victory Capital Management Inc. Grows Stake in Progyny, Inc. (NASDAQ:PGNY)

Victory Capital Management Inc. raised its stake in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) by 79.4% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 203,277 shares of the company's stock after purchasing an additional 89,941 shares during the period. Victory Capital Management Inc. owned approximately 0.24% of Progyny worth $3,507,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in PGNY. GAMMA Investing LLC lifted its holdings in shares of Progyny by 341.4% in the fourth quarter. GAMMA Investing LLC now owns 1,611 shares of the company's stock valued at $28,000 after purchasing an additional 1,246 shares in the last quarter. Nisa Investment Advisors LLC lifted its stake in Progyny by 108.4% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company's stock valued at $51,000 after acquiring an additional 1,526 shares in the last quarter. Caitlin John LLC boosted its holdings in Progyny by 2,974.8% during the 4th quarter. Caitlin John LLC now owns 3,290 shares of the company's stock worth $57,000 after acquiring an additional 3,183 shares during the last quarter. SBI Securities Co. Ltd. purchased a new position in Progyny during the 4th quarter worth $74,000. Finally, Meeder Asset Management Inc. bought a new stake in shares of Progyny in the 3rd quarter worth $77,000. 94.93% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, Chairman David J. Schlanger acquired 150,000 shares of the firm's stock in a transaction that occurred on Thursday, December 26th. The shares were bought at an average cost of $14.68 per share, for a total transaction of $2,202,000.00. Following the purchase, the chairman now owns 228,269 shares in the company, valued at $3,350,988.92. This trade represents a 191.65 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Peter Anevski bought 209,500 shares of the business's stock in a transaction on Monday, December 23rd. The stock was bought at an average price of $14.48 per share, with a total value of $3,033,560.00. Following the purchase, the chief executive officer now owns 441,463 shares in the company, valued at $6,392,384.24. This trade represents a 90.32 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 12.30% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on PGNY shares. Canaccord Genuity Group boosted their price target on shares of Progyny from $17.00 to $23.00 and gave the stock a "hold" rating in a report on Friday, February 28th. JPMorgan Chase & Co. lifted their target price on shares of Progyny from $17.00 to $23.00 and gave the stock a "neutral" rating in a research report on Tuesday, January 28th. Finally, Bank of America upped their target price on Progyny from $21.00 to $25.00 and gave the company a "buy" rating in a report on Tuesday, February 11th. Nine analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $24.82.

Progyny Trading Down 0.2 %

Shares of PGNY stock traded down $0.05 on Thursday, hitting $21.66. 531,654 shares of the stock were exchanged, compared to its average volume of 1,590,678. The firm's 50 day moving average is $21.80 and its two-hundred day moving average is $18.61. Progyny, Inc. has a one year low of $13.39 and a one year high of $38.98. The firm has a market capitalization of $1.85 billion, a PE ratio of 37.45, a P/E/G ratio of 2.39 and a beta of 1.41.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.